Pancreatic cancer remains one of the most difficult cancers to treat, with a 5-year survival rate of only 7%. Pancreatic cancer is treated with surgery, chemotherapy and radiation. A treatment that targets the stroma around a pancreatic cancer and makes blood vessels leaky, thereby facilitating the entry of chemotherapy drugs into the cancer cells, could help in the treatment of pancreatic cancer.
Approximately 30 percent of acute intracranial hemorrhage (AHT) diagnoses are missed when caretakers provide inaccurate histories or when infants have nonspecific symptoms such as vomiting or fussiness. A blood test that could help clinicians identify infants who may have had bleeding of the brain as a result of abusive head trauma, sometimes referred to as shaken baby syndrome has been developed.
The U.S. Food and Drug Administration (FDA) has approved the use of the directly acting agents (DAAs) sofosbuvir (available as Sovaldi) and the combination of ledipasvir and sofosbuvir (available as Harvoni) for the treatment of hepatitis C in children and adolescents between the ages of 12 to 17 years, thereby increasing the possible number of beneficiaries of this new treatment.